Send Comments to IFOND

International Foundation for Optic Nerve Disease

 

We fund research on causes, prevention and treatment. We fund hope.

LHON | Glaucoma | Toxic | Ischaemic | Impact | Projects | Donors | Coping | Glossary | Links | About | LHON Registry | Contact | Home

IFOND Dictionary: Index | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | NUM

News: LHON IFOND research | LHON treatment prospects | Mitochondrial Genome Editing | LHON talks | Pay it forward | Mitochondrial Regulation | Avoid BAK eye drop preservative, etc. | We experiment with cigarette smoke so you need not. | Viral vector trials | EPI-743 LHON trials | Idebenone LHON treatment
Digests: NEI News | Mitochondrial Disease News LHON | ARVO Journals LHON | PubMed LHON | Europe PMC LHON | MRC-MBU news | Sadun Lab Abstracts

Glaucoma

Glaucoma is a group of eye diseases where vision is lost due to damage to the optic nerve. Glaucoma affects many millions of people worldwide. Glaucoma is the second-leading cause of blindness worldwide after cataracts. In the United States about 7% of the population 65 years and older is affected. Peripheral vision may begin to decrease followed by central vision resulting in blindness if not treated. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. In the past the various forms of glaucoma were thought to be solely due to mechanical problems: either increased pressure on the optic nerve from some form of trauma, or decreased blood flow (ischemia) to the optic nerve. However, it has long been apparent that increased pressure throughout the eye only damages certain cells in the eye and that the drugs used to decrease the pressure, though sight-saving, do not completely stop the progressive visual loss. Current research offers an explanation for why this is so.

Glaucoma is increasingly thought of as a neurodegenerative disease rather than a simple mechanical problem. The same neurochemical events leading to neuronal cell death in ischemic optic neuropathy also occurs in glaucoma. There is still much to be learned about how glaucoma causes visual loss, but enough is already known for researchers in many laboratories to be on the hunt for ways to protect nerve cells from damage in glaucoma. Results of this important research may impact treatments for other optic nerve and neurodegenerative diseases.


Update history

Last edited: 1 June 2026


IFOND welcomes questions and comments

LHON | Glaucoma | Toxic | Ischaemic | Impact | Projects | Donors | Coping | Glossary | Links | About | LHON Registry | Contact | Home


Use Zelle to donate to our Bank of America account with our email, ifond@aol.com
or
Donate ForGood
or
Donate directly to IFOND at the address below.

Other ways to give:

Stock transfers: Stocks, bonds and similar instruments can be transfered directly to IFOND as donations.
Matching gifts: Many employers will match IFOND donations given by employees.
Gifts in kind: Property, items of appreciable value and service can be donated directly to IFOND.
Legacy, bequests, planned gifts: Make IFOND the beneficiary of your will, insurance policy, bank account, real estate or other.
Gifts of solidarity and remembrance: Bestow a gift to IFOND in honour of a cherished, or important person.
Project specific option: Instruct IFOND which area of research to support with your donation.


The International Foundation for Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
Phone: 8455221972
Email: ifond@aol.com
Web site: https://www.ifond.org/


IFOND is registered service mark of The International Foundation for Optic Nerve Disease, est. October 1995.

Copyright 1999-2026, International Foundation for Optic Nerve Disease.


The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.